NEW YORK (GenomeWeb) – Cynvenio Biosystems announced today that it has launched a pilot surveillance study with South Korea's ATGen Global to evaluate a new method for the early detection of cancer recurrence in triple-negative breast cancer patients. Cynvenio's ClearID test will be combined with ATGen's NK Vue blood test to detect cancer recurrence in women who have previously been treated for triple-negative breast cancer and show no radiographic signs of metastases.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.